Pfizer, ADCs and Ivonescimab

Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc.
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials
Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates (ADCs) for solid tumor treatments.
Summit Therapeutics announces clinical trial collaboration with Pfizer
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF
Summit Therapeutics shares rise on Pfizer trial collaboration
Summit Therapeutics Inc. (NASDAQ: NASDAQ: SMMT) stock climbed 5% after the biopharmaceutical company announced a clinical trial collaboration with industry giant Pfizer Inc. (NYSE: NYSE: PFE ). The partnership is set to evaluate Summit's ivonescimab in combination with Pfizer's antibody drug conjugates (ADCs) for the treatment of multiple solid tumor types.
Summit Therapeutics jumps 5% to $23.19 after trial pact with Pfizer
EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE) Published first on TheFly – the ultimate source for
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
FierceBiotech12h
Pfizer to test Summit's white-hot bispecific with ADCs
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss
Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...
BioPharma Dive8h
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Just like AI, China’s biotech is disrupting the world. Is the US ready?
Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...
3 Stocks That Could Trounce the Market in 2025
But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...